Spotlight Medical funding news – Paris-based Spotlight Medical Secures €6.2 Million in a Seed Funding

This funding will enable Spotlight Medical to bring its first prognosis test to the clinic, marking a significant milestone in the commercialization of AI-based solutions for cancer treatment. By leveraging decades of patient treatment data, Spotlight Medical aims to ensure that no patient is over or undertreated, ultimately improving cancer outcomes.

Benjamin Belot from Kurma Partners. Christian Lautner from Heal Capital Kurma Partners and Heal Capital said, “We were impressed by the quality of the team and by their unique technology, quite different from what we usually see in the field of precision oncology, We are convinced the Spotlight Medical team is perfectly positioned to bring an AI-empowered precision oncology platform to clinical practice and thereby have a lasting impact on patients’ lives.”

Sylvain Berlemont, CEO of Spotlight Medical said, “We are thrilled to have the support of Kurma Partners and Heal Capital as we take this critical step towards transforming cancer treatment, This investment will accelerate our mission to harness the power of AI in analyzing patient data, providing physicians with the insights they need to make more informed treatment decisions.”

Founded in 2024 and backed by world-renowned cancer centers Institut Curie and Gustave Roussy, Spotlight Medical is dedicated to developing clinical tests that exploit the vast amount of information contained in patient data. By using advanced AI algorithms, the company aims to provide the first concrete AI-based solution for cancer patients, significantly enhancing the precision of cancer treatment.

Read also - Hi-Tech Apparel Acquisition news – London-based Unmade has been Acquired by Hi-Tech Apparel

About Spotlight Medical

Spotlight Medical is a precision medicine company striving to free all patients from cancer through a better understanding of each patient’s unique disease. They develop advanced AI tests that enhance treatment selection by leveraging decades of patient data.

This ensures personalized and effective care for each individual, significantly improving patient outcomes and quality of life. By closely collaborating with physicians, we create impactful tests that address critical unmet clinical needs, opening a new era in cancer care.